515 related articles for article (PubMed ID: 29788127)
61. Upfront tofacitinib in patients with biological-naïve ulcerative colitis - An Indian multicentric experience.
Giri S; Bhrugumalla S; Kamuni A; Mishra D; Pati GK; Agrawal D; Verma G; Wagh R; Chauhan S; Ingle M; Chandnani S; Jain S; Rathi PM; Shukla A; Kale A
Indian J Gastroenterol; 2024 Feb; 43(1):237-243. PubMed ID: 37726491
[TBL] [Abstract][Full Text] [Related]
62. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.
Matsuoka K; Hisamatsu T; Kim HJ; Ye BD; Arai S; Hoshi M; Yuasa H; Tabira J; Toyoizumi S; Shi N; Woo JS; Hibi T
J Gastroenterol Hepatol; 2022 Oct; 37(10):1884-1892. PubMed ID: 35734858
[TBL] [Abstract][Full Text] [Related]
63. JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature.
Sánchez González CO; Nieto González JC
Reumatol Clin (Engl Ed); 2022 Oct; 18(8):453-458. PubMed ID: 34893459
[TBL] [Abstract][Full Text] [Related]
64. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott IC; Hider SL; Scott DL
Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
[TBL] [Abstract][Full Text] [Related]
65. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Asahina A; Etoh T; Igarashi A; Imafuku S; Saeki H; Shibasaki Y; Tomochika Y; Toyoizumi S; Nagaoka M; Ohtsuki M;
J Dermatol; 2016 Aug; 43(8):869-80. PubMed ID: 26875540
[TBL] [Abstract][Full Text] [Related]
66. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure.
Burmester GR; Nash P; Sands BE; Papp K; Stockert L; Jones TV; Tan H; Madsen A; Valdez H; Cohen SB
RMD Open; 2021 May; 7(2):. PubMed ID: 34045358
[TBL] [Abstract][Full Text] [Related]
67. Efficacy of JAK inhibitors in Ulcerative Colitis.
Ferrante M; Sabino J
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S737-S745. PubMed ID: 31879750
[TBL] [Abstract][Full Text] [Related]
68. Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review.
Winthrop K; Isaacs J; Calabrese L; Mittal D; Desai S; Barry J; Strengholt S; Galloway J
Semin Arthritis Rheum; 2023 Feb; 58():152120. PubMed ID: 36347212
[TBL] [Abstract][Full Text] [Related]
69. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
[TBL] [Abstract][Full Text] [Related]
70. Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.
Antonelli E; Torti G; Bassotti G
J Clin Gastroenterol; 2019 Oct; 53(9):635-640. PubMed ID: 31373941
[TBL] [Abstract][Full Text] [Related]
71. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
Teixeira FV; Damião AOMC; Kotze PG
Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
[TBL] [Abstract][Full Text] [Related]
72. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
73. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
Nakase H
Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
[TBL] [Abstract][Full Text] [Related]
74. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
Abdulrahim H; Sharlala H; Adebajo AO
Expert Opin Pharmacother; 2019 Nov; 20(16):1953-1960. PubMed ID: 31456440
[No Abstract] [Full Text] [Related]
75. JAK inhibition in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
[TBL] [Abstract][Full Text] [Related]
76. The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database.
Seo GH; Jung SH
J Korean Med Sci; 2022 Apr; 37(16):e123. PubMed ID: 35470598
[TBL] [Abstract][Full Text] [Related]
77. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
78. Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease?
Biemans VB; Verstockt B
United European Gastroenterol J; 2020 Aug; 8(7):753-754. PubMed ID: 32640933
[No Abstract] [Full Text] [Related]
79. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation.
Baumrin E; Van Voorhees A; Garg A; Feldman SR; Merola JF
J Am Acad Dermatol; 2019 Jul; 81(1):102-110. PubMed ID: 30885757
[TBL] [Abstract][Full Text] [Related]
80. Cellular and functional actions of tofacitinib related to the pathophysiology of hibernoma development.
Radi ZA; Vogel WM; Bartholomew PM; Koza-Taylor P; Papanikolaou A; Wisialowski T; Nambiar P; Ball DJ
Regul Toxicol Pharmacol; 2017 Dec; 91():93-102. PubMed ID: 29074274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]